Article Information
History
- September 22, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Garazi Serna1,
- Eloy García2,
- Roberta Fasani1,
- Xavier Guardia1,
- Tomas Pascual3,4,5,
- Laia Paré6,
- Fiorella Ruiz-Pace7,
- Antonio Llombart-Cussac8,
- Javier Cortes9,
- Aleix Prat3,4,5 and
- Paolo Nuciforo1,5,*
- 1Molecular oncology group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 2Department of Mathematics and Informatics, University of Barcelona, Barcelona, Spain
- 3Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
- 4Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain
- 5SOLTI Breast Cancer Research Group, Barcelona, Spain
- 6Reveal Genomics, Barcelona, Spain
- 7Oncology Data Science Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 8Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain; FISABIO, Universidad Católica de Valencia, Spain
- 9International Breast Cancer Center (IBCC), Quirónsalud Group, Barcelona, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain
- ↵*Corresponding author: Paolo Nuciforo, MD, PhD, Molecular Oncology Group, Vall d’Hebron Institute of Oncology, pnuciforo{at}vhio.net